PRESENTER: Dennis Kerrigan, PhD, FACSM, ACSM-CEP; Henry Ford Health
BRIEF SUMMARY
This presentation will provide an overview of the latest interventions to combat obesity, a serious public health epidemic with complex, social, physiological, and psychological interactions. In addition to reviewing the efficacy of various behavioral, medical, and surgical approaches, this presentation will focus on the role of the clinical exercise physiologist (CEP) as a key member of a multidisciplinary weight management team. Specifically, how the unique skill set of CEPs contributes to improving outcomes,
especially for high risk, complicated patients.
Cost: FREE
- CEPA members: FREE
- Non-members: $50 -- Join today, then register for free. Join Today
CECs: 1 (one) CEC
RECORDING: This event will be recorded. Access to a recording of this event will be available to all who register for 3 months after the event.
LEARNING OBJECTIVES
- Understand key determinants of obesity
- Understand current obesity trends and prevalence
- Understand key weight loss intervention trials
- Understand weight loss medications, including GLP-1 agonists
- Understand surgical approaches to weight loss
- Understand the potential role of CEPs for developing weight loss exercise interventions, supporting physician and dietary recommendations, and providing surveillance and communication with the rest of the health care team
ABOUT THE PRESENTER
Dr. Kerrigan is a clinical exercise physiologist and the Director of Outpatient Exercise Programs and Weight Management at Henry Ford Hospital’s campus in Detroit Michigan. He earned his B.S. from Bowling Green State University (1998), M.S. from Eastern Michigan University (2002), and Ph.D. from The Ohio State University (2008). In his current role he oversees the ExCITE program, a comprehensive, evidence-based clinical exercise program for patients with history of cancer. In addition to his clinical duties, Dr. Kerrigan also conducts research in patients with heart disease, cancer, and obesity. He was the primary investigator for the Rehab-VAD trial, the first randomized trial of cardiac rehabilitation in patients in the United States with left ventricular assist devices. He was also the PI in the HF-PROACTIVE trial, a trial examining the potential preventive effects of exercise training in patients with early markers of chemotherapy induced cardiotoxicity. Currently he is a site PI in a study lead by Dr. Brian Callahan (University of Michigan) examining the effects of bariatric surgery and high intensity interval training on distal symmetric polyneuropathy. He is a past President of the Clinical Exercise Physiology Association (CEPA).